Alembic Pharmaceuticals has scheduled a series of one-on-one meetings with institutional investors to discuss business updates and performance. The management will engage with representatives from HDFC Mutual Fund, Tata Mutual Fund, and DSP Mutual Fund through in-person sessions in Mumbai, followed by a virtual interaction with HDFC Life Insurance Company Limited. These meetings are part of the company's routine investor relations outreach to maintain transparency with key stakeholders.

The interactions are set to take place between June 22 and June 25, 2026. The first two meetings will be held physically in Mumbai, while the session with the insurance provider will be conducted via video conferencing. The company has explicitly stated that no unpublished price sensitive information will be shared during these discussions, ensuring compliance with regulatory norms.

Meeting Schedule

The following table details the scheduled investor interactions:

The disclosure was formally submitted to the stock exchanges on June 19, 2026. Manisha Saraf, Company Secretary of alembic pharmaceuticals , signed the intimation regarding these investor interactions.

Alembic Pharmaceuticals has received tentative approval from the US Food and Drug Administration (USFDA) for Binimetinib Tablets, 45 mg. This approval positions the company as the sole first applicant for the product, potentially granting it 180 days of generic marketing exclusivity in the US market upon final approval. The drug addresses a significant market need, with an estimated market size of $259 million for the twelve months ending March 2026, according to IQVIA.

Approval Details and Therapeutic Indication

The tentative approval was granted for the company's Abbreviated New Drug Application (ANDA) for Binimetinib Tablets, 45 mg. This product is therapeutically equivalent to the reference listed drug Mektovi Tablets, 15 mg, marketed by Array. Binimetinib is a kinase inhibitor indicated for the treatment of patients with unresectable or metastatic melanoma with a BRAF V600E or V600K mutation, in combination with encorafenib. It is also indicated for the treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) with a BRAF V600E mutation.

Market Position and Exclusivity

Based on the FDA's Paragraph IV Certifications List, Alembic is the first applicant to have filed its ANDA containing a Paragraph IV certification for this dosage. Consequently, upon final approval, the company may be eligible for 180 days of marketing exclusivity. Alembic had previously received tentative approval for Binimetinib Tablets, 15 mg.

Key Metrics